Table 2 Lymphocyte frequencies (mean %) after ovx in WT and Ncf1-deficient mice (n = 6–9 mice per group, t-test comparing ovx vs. sham for each genotype)
From: Ncf1 affects osteoclast formation but is not critical for postmenopausal bone loss
Leukocyte population | Sub population | WT Sham (%, ±SD) | WT ovx (%, ±SD) | p-value | Ncf1*/* Sham (%, ±SD) | Ncf1*/* ovx (%, ±SD) | p-value |
|---|---|---|---|---|---|---|---|
4 weeks after ovx | |||||||
DCs (CD11c+) | 2.5 ± 0.9 | 2.4 ± 0.2 | n.s. | 2.3 ± 0.7 | 2.6 ± 0.5 | n.s. | |
MHC II+ | 44 ± 10 | 44 ± 9.2 | n.s. | 49 ± 16 | 51 ± 16 | n.s. | |
CD80+ | 19 ± 3.8 | 17 ± 4.3 | n.s | 18 ± 4.1 | 25 ± 8.4 | 0.04 | |
T-cell (CD4+) | 1.6 ± 0.3 | 0.8 ± 0.2 | <0.0001 | 1.2 ± 0.3 | 0.93 ± 0.3 | 0.04 | |
CD69+ | 22 ± 6 | 26 ± 5.5 | n.s | 24 ± 8.8 | 33 ± 8.0 | n.s | |
T cell (CD8+) | 1.4 ± 0.2 | 0.74 ± 0.2 | <0.0001 | 0.94 ± 0.4 | 0.8 ± 0.3 | n.s | |
CD69+ | 17 ± 7.4 | 23 ± 3.7 | n.s | 21 ± 7.7 | 25 ± 8.0 | n.s | |
2 weeks after ovx | |||||||
DCs (CD11c+) | 7.3 ± 0.9 | 6.6 ± 0.1 | n.s. | 6.6 ± 1.0 | 6.2 ± 1.1 | n.s. | |
MHC II+ | 40 ± 6.0 | 38 ± 2.9 | n.s. | 37 ± 4.8 | 36 ± 4.4 | n.s. | |
CD80+ | 30 ± 3.0 | 24 ± 3.2 | 0.001 | 31 ± 4.2 | 25 ± 4.6 | 0.03 | |
T-cell (CD4+) | 2.1 ± 0.5 | 0.7 ± 0.2 | <0.0001 | 2.3 ± 0.6 | 1.1 ± 0.5 | 0.001 | |
CD69+ | 21 ± 5.3 | 33 ± 8.4 | 0.002 | 19 ± 6.5 | 26 ± 3.2 | 0.02 | |
T cell (CD8+) | 2.2 ± 0.9 | 0.8 ± 0.2 | <0.001 | 2.0 ± 1.3 | 0.56 ± 0.16 | 0.01 | |
CD69+ | 9.8 ± 2.3 | 19 ± 5.0 | <0.001 | 12 ± 3.7 | 25 ± 8.5 | 0.002 | |